A new drug used to treat advanced melanoma patients with a specific genetic mutation in their tumors demonstrated significant tumor shrinkage in the majority of patients during a clinical trials.
- ‘Docking stations’ on chromosomes new anti-cancer target
- VICC’s Johnson to study cancer survivorship with immune inhibitor drugs
- Team blends high-end imaging techniques
- Barocas named to Commission on Cancer
- Home Page
- Feature: Did You Smoke?
- Feature: DNA Mechanics
- Feature: Words to Live By
- Feature: Cancer Care Gets Personal
- Director's Letter
- A Closer Look
- Spotlight on Multiple Myeloma
- Stories of Survival
- Quick Takes
- Journal Watch